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Abstract
Background: Bleeding tendencies can occur with uremia.
Objectives: To characterize primary hemostatic function in dogs with acute kidney
injury (AKI).
Animals: Ten dogs with International Renal Interest Society AKI grade III or above
and 10 healthy controls.
Methods: Prospective study comparing PCV, platelet count, platelet aggregometry
(Multiplate), and von Willebrand factor antigen to collagen binding activity ratio
(vWF:Ag:vWF:CBA) in 2 groups of dogs (AKI group versus controls). Buccal mucosal
bleeding time was measured in the AKI group only. Data are presented as median
[25th, 75th percentile] unless otherwise stated. Significance was set at P < .05.
Results: Mean PCV was significantly lower in the AKI (34.7%; ±SD, 8.8) than in the
control (46.1%; ±SD, 3.6; P < .001) group. Platelet count was significantly higher in the
AKI (350.5 × 103/μL [301, 516]) than in the control (241 × 103/μL [227, 251]; P = .01)
group. Collagen-activated platelet aggregometry measured as area under the curve was
significantly lower in the AKI (36.9 ± 17.7) than in the control (54.9 ± 11.2; P = .05)
group. vWF:Ag:vWF:CBA was significantly higher in the AKI (2.2 [1.9, 2.6]) than in the
control (1.1 [1.1, 1.2]; P = .01) group. There was a strong correlation between vWF:Ag:
vWF:CBA and creatinine (r = 0.859; P < .001), but no other variables.
Conclusions and Clinical Importance: Dogs with AKI had decreased collagen-
activated platelet aggregation and appear to have a type II von Willebrand disease-
like phenotype as indicated by the high vWF:Ag:vWF:CBA.
K E YWORD S
buccal mucosal bleeding time, platelet aggregometry, renal, thrombocytopathia, von
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1 | INTRODUCTION
Acute kidney injury (AKI) represents a spectrum of acute diseases,
encompassing a continuum of functional and parenchymal damage.
The resultant renal injury will depend on the functional origin, sever-
ity, and duration of the conditions inciting kidney injury (www.iris-
kidney.com/guidelines). Dogs with AKI might require invasive
procedures such as renal biopsies for diagnosis, prognostication, and
Abbreviations: AA, arachidonic acid; ADP, adenosine diphosphate; AKI, acute kidney injury;
AoCKD, acute-on-chronic kidney disease; AUC, area under the curve; AVWS, acquired von
Willebrand syndrome; BMBT, buccal mucosal bleeding time; CKD, chronic kidney disease;
COL, collagen; GP, glycoprotein; IRIS, International Renal Interest Society; LTA, light
transmittance aggregometry; MEPA, multiple electrode impedance platelet aggregometry;
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treatment.1 Other invasive procedures such as placement of central
venous catheters, dialysis catheters for renal replacement treatment,
peritoneal catheters for peritoneal dialysis,2,3 or feeding tube place-
ment for longer term management might also be required.4
Uremic bleeding occurs in people with chronic kidney disease
(CKD) due to abnormalities in primary hemostasis.5-7 Intrinsic factors
including platelet secretion defects, abnormal platelet-vessel wall inter-
actions including von Willebrand Factor (vWF) abnormalities, increased
platelet inhibitors, uremic toxins, as well as factors such as anemia, if
present, contribute to bleeding.5-7 Extrinsic factors might also be
involved, including medications, comorbidities, and iatrogenic factors
such as extracorporeal circulation.5-7 Although these mechanisms are
well described in people with CKD, the understanding of uremic bleed-
ing in dogs with AKI is limited.8,9
It is known that platelet function is altered in uremic dogs; how-
ever, the mechanisms are not clearly understood. In experimental
models of kidney injury, prolongation in buccal mucosal bleeding time
(BMBT) and decreased platelet glass bead retention percentage occurs
without significant changes in arachidonic acid (AA)-, adenosine
diphosphate (ADP)-, collagen (COL)-, and epinephrine-induced light
transmittance aggregometry (LTA).10 In addition, vWF antigen concen-
trations (vWF:Ag) increases,11 suggesting 1 of the mechanisms of
bleeding to be due to abnormalities in platelet adhesion independent
of vWF or platelet agonists. In dogs with naturally occurring CKD, sig-
nificant changes in AA-, ADP-, and COL-induced multiple electrode
impedance platelet aggregometry (MEPA) does not occur despite clini-
cal bleeding.12 However, platelet dysfunction as measured by the
platelet function analyzer-100 does occur.13
Despite wide acceptance that platelet dysfunction occurs in people
with CKD,5-7 there is not a comprehensive understanding of hemostatic
defects in dogs with naturally occurring AKI. Therefore, the primary
objective of this study was to characterize primary hemostatic function
measured by AA-, ADP-, and COL-induced MEPA, and vWF assays in
dogs with naturally occurring AKI. The secondary objective was to
determine if BMBT can be used to predict primary hemostatic dysfunc-
tion in dogs with AKI when compared to MEPA and vWF assays. We
hypothesized that (1) there will be no difference in AA-, ADP-, and
COL-induced MEPA between dogs with AKI and healthy dogs; (2) there
will be no difference in vWF:Ag, vWF collagen binding activity (vWF:
CBA), and vWF:Ag to vWF:CBA ratio (vWF:Ag:vWF:CBA) between
dogs with AKI and healthy dogs; and (3) there will be strong correlation
between BMBT and these primary hemostatic variables measured.
2 | MATERIALS AND METHODS
This prospective observational cohort study was approved by the Ethics
and Animal Welfare Committee of the Royal Veterinary College (refer-
ence number 2014 1305), with owner consent obtained for all dogs
enrolled. Client-owned dogs admitted to the QueenMother Hospital for
Animals of the Royal Veterinary College between June 2015 and July
2016 with International Renal Interest Society (IRIS) AKI grade III or
higher were enrolled as the AKI group. Dogs were assigned an IRIS AKI
grade III based on a serum creatinine concentration ≥2.6 mg/dL
(www.iris-kidney.com/guidelines/grading); an acute onset of clinical
signs attributable to AKI including listlessness, vomiting, diarrhea, and
anorexia; exclusion of prerenal causes of azotemia by documentation of
isosthenuria (urine specific gravity of 1.007 to 1.015) before IV fluid
therapy (excluding other causes of isosthenuria); azotemia in the pres-
ence of euvolemia or hypervolemia based on clinical assessment; and
exclusion of post-renal causes based on the attending clinicians assess-
ment. Dogs with acute-on-chronic kidney disease (AoCKD) were
included in the study. Chronic kidney disease was diagnosed based on
the presence of 1 of more of the following: (1) history of polyuria and
polydipsia, (2) being previously diagnosed with kidney disease, (3) pres-
ence of nonregenerative anemia with no evidence of recent hemor-
rhage, (4) ultrasonographical changes supportive of CKD reported by
a board-certified veterinary radiologist, and (5) histological diagnosis
reported by a board-certified anatomical pathologist. A diagnosis of
AoCKD was made based on acute onset of clinical signs attributable to
azotemia with evidence of CKD. Dogs were excluded from the study if
they weighed <3.5 kg; received anticoagulants, starch-based colloids,
antiplatelet, or nonsteroidal anti-inflammatory drug treatment during
the preceding 14 days; were thrombocytopenic with a platelet count
of <100 × 103/μL; were anemic with a PCV of <20%; had a diagnosis
of sepsis including pyelonephritis but not excluding leptospirosis; were
of a breed with a hereditary predisposition to platelet dysfunction
including Greyhounds, Cavalier King Charles Spaniels, and Doberman
Pinschers; or if minimum database including CBC (Advia 2120i, Sie-
mens, UK) with platelet count confirmed by a board-certified clinical
pathologist, biochemistry (iLAB 600; Werfen, New Delhi, India) with
urea and creatinine measurements, urinalysis, and urine culture and
specificity were not obtained.
Healthy dogs were enrolled as the control group from the hospital
blood donor program. The number of dogs in the control group matched
the number of dogs in the AKI group. All dogs were between 1 and
8 years of age, with body weight greater than 25 kg; had not received
any medication during the preceding 14 days; and were deemed healthy
based on physical examination, CBC (Advia 2120i, Siemens), and serum
biochemistry (iLAB 600, Werfen). Any dogs within the blood donor
program with a breed predisposition to platelet dysfunction including
Greyhounds and Doberman Pinschers were excluded from the study.
Once a diagnosis of AKI was made, client consent for study enrol-
ment was obtained, and diagnostic tests and treatment were per-
formed at the discretion of the attending clinician. Age, breed, sex, and
minimum database as described above were collected before or during
the study, and additional information including evidence of clinical
bleeding and final diagnosis was obtained from medical records after
the study was concluded. When routine blood sampling was required
at the discretion of the attending clinician, a 21-gauge blood collection
system (BD Safety-Lok, Becton Dickinson, UK) was inserted in the jug-
ular or saphenous vein, and 1.8 mL of blood was collected in a 3.2%
sodium citrate anticoagulated vacutainer tube (BD Vacutainer, Becton
Dickinson), 1.5 mL of blood was collected in a hirudin anticoagulated
vacutainer tube (Roche Diagnostic International Limited, Rotkreuz,
Switzerland), and remaining blood samples were collected at the
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discretion of the attending clinician. Dogs in the control group had a
21-gauge blood collection system (BD Safety-Lok) inserted in
the saphenous vein, and 3 mL of blood collected in an
ethylenediaminetetraacetic acid anticoagulated vacutainer tube
(Cell-Dyn 2500; Abbott Diagnostics, Abbott Park, Illinois) and 3.5 mL
of blood collected in a silica-coated vacutainer tube (ILAB
600, Holliston, Massachusetts) for routine hematology and biochemis-
try, respectively, followed by 1.8 mL of blood collected in a 3.2%
sodium citrate anticoagulated vacutainer tube (BD Vacutainer), and
1.5 mL of blood collected in a hirudin anticoagulated vacutainer tube
(Roche Diagnostic International Limited). The hirudin anticoagulated
blood was always collected as the second or subsequent sample in
both groups to prevent venepuncture-induced platelet activation.
Arachidonic acid (ASPItest, Roche Diagnostic International Limited),
ADP (ADPtest, Roche Diagnostic International Limited), and COL-
activated (COLtest, Roche Diagnostic International Limited) MEPA
(Multiplate) (Roche Diagnostic International Limited) were performed
on the hirudin anticoagulated blood samples according to a previously
published protocol within 30 to 120 minutes of sample collection.14
Changes in electrical impedance were measured, and area under the
curve (AUC) of aggregation units over a 6-minute interval was
reported. Area under the curve of aggregation units was measured in
duplicate with results reported as the mean of the duplicate measure-
ments. Measurements were repeated if Pearson's correlation coeffi-
cient and the difference between the 2 areas under the curve were
less than 0.98 or greater than 20%, respectively. Reference intervals
for MEPA were generated from sampling of 34 blood donors that were
considered healthy based on history, clinical examination, hematology,
and biochemistry. As the sample size was small, Horn's method was
used for outlier detection and robust method was used for the calcula-
tion of reference intervals.15 This was implemented using refLimit
function from <referenceIntervals> package in the R software
(R Studio, version 1.1.456, Boston, Massachusetts).
Sodium citrate anticoagulated blood was centrifuged at 2500g for
20 minutes at 4C within 30 minutes of sample collection. After centri-
fugation, plasma was collected and stored at −80C for no longer than
6 months. Von Willebrand Factor antigen concentrations, vWF:CBA,
and vWF:Ag:vWF:CBA were measured from the citrated plasma by an
external laboratory as previously described.16,17 Reference interval for
these values was developed by the same external laboratory (Cornell
University Animal Health Diagnostic Centre, Ithaca, New York).
Buccal mucosal bleeding time was performed only in the AKI
group, and this occurred within 2 hours of aforementioned blood sam-
ple collection. This procedure was performed according to published
protocols,18,19 by 2 primary investigators. If bleeding from the incision
site continued beyond 10 minutes, BMBT was discontinued by apply-
ing digital hemostasis until bleeding discontinued.
Shapiro–Wilk test for normality was performed on age, body
weight, AA AUC, ADP AUC, COL AUC, vWF:Ag, vWF:CBA, wVF:Ag:
vWF:CBA, PCV, platelet count, creatinine, and urea with P > .05 being
normally distributed. Of the data that were normally distributed,
Levene's test for equality of variance was performed in which equal
variance was assumed if P > .05. Student's t-test was performed to
compare the magnitude of difference if the data were normally dis-
tributed and equal variance assumed; otherwise, Mann–Whitney
U test was performed with P < .05 being significantly different. Spe-
arman's rank was used to measure correlations between all the
above-mentioned continuous variables in addition to BMBT. Statisti-
cal analyses were performed using commercially available software
(IBM SPSS Statistics for Windows, version 25.0, Armonk, New York).
3 | RESULTS
During the recruitment period, 58 dogs presented with AKI, and from
these, 10 dogs met the inclusion criteria for the AKI group and 10 con-
trol dogs were enrolled to match this number. Within the AKI group,
2 were male entire, 4 were male neutered, and 4 were female
neutered. Within the control group, 4 were male entire, 4 were male
neutered, 1 was female entire, and 1 was female neutered. Breeds in
the AKI group included a German Shepherd Dog cross, Jack Russell
Terrier, Cairn Terrier, Labrador Retriever, Golden Retriever, Border
Collie, Boston Terrier, English Springer Spaniel, and 2 crossbreed dogs.
Breeds included in the control group included 4 Labrador Retrievers,
2 German Shepherd Dogs, 2 German Shepherd Dog crosses, 1 Boxer,
and 1 Pyrenean Mountain Dog. There were significant differences in
age and body weight between the 2 groups (Table 1).
The final diagnosis of AKI included 5 dogs with AoCKD for which
a reason for the acute deterioration was not identified, and 1 dog with
AKI secondary to each of the following diagnoses: hypertensive
nephropathy secondary to pheochromocytoma, leptospirosis, cutane-
ous and renal glomerular vasculopathy, pancreatitis, and gentamicin
administration with associated pancreatitis.
Invasive procedures were performed in 6 dogs in the AKI group,
including nasoesophageal tube placement, esophagostomy tube place-
ment, renal biopsy, bone marrow biopsy, and prostatic wash with no evi-
dence of clinical bleeding. Three dogs had gastrointestinal hemorrhage;
however, the underlying cause was not determined. One dog was anemic
at the time of admission with a PCV and total protein (TP) of 28% and
4.3 g/dL, respectively, with no clinical bleeding despite nasoesophageal
tube placement. One dog was anemic with a PCV and TP of 14% and
4.8 g/dL, respectively, at the time of hospital admission with no clinical
sign of bleeding despite esophagostomy tube placement. This dog was
included in the study after receiving a blood transfusion. Two dogs had
decreasing PCV with 1 requiring 2 blood transfusions after the study
period, despite no evidence of clinical bleeding.
Packed cell volume (P = .001), COL AUC (P = .05), and vWF:CBA
(P = .04) were significantly lower in the AKI group compared to the
control group, although COL AUC remained within reference interval.
Platelet count (P = .01), creatinine (P < .001), urea (P < .001), and
vWF:Ag:vWF:CBA (P = .001) were significantly higher in the AKI
group compared to the control group. There was no significant differ-
ence between the 2 groups in other measured variables (Table 1).
There was no significant difference in any variable between the dogs
with AoCKD and dogs with no underlying CKD (data not presented).
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Buccal mucosal bleeding time was performed on 9 of the 10 dogs
in the AKI group. One dog did not have BMBT performed due to clini-
cal concerns that the BMBT procedure might result in worsening ane-
mia due to the small size of the dog and low MEPA AUC. The mean
and standard deviation (SD) of BMBT in dogs with AKI was 5.09
(±2.68) minutes (reference interval, 1.8-4.8 minutes18).
There was a strong correlation between creatinine and age
(r = 0.721, P < .001); creatinine and vWFAg:CBA (r = 0.859, P < .001);
ADP and COL (r = 0.745, P < .001); urea and platelet count (r = 0.746,
P < .001); and urea and creatinine (r = 0.716, P < .001). There was
moderate correlation between creatinine and PCV (r = −0.628,
P = .003); creatinine and vWF:CBA (r = −0.621, P = .004); vWF:Ag:
vWF:CBA and PCV (r = −0.519, P = .02); vWF:Ag:vWF:CBA and vWF:
Ag (r = 0.506, P = .02); vWF:Ag:vWF:CBA and vWF:CBA (r = −0.542,
P = .01); vWF:Ag:vWF:CBA and age (r = 0.583, P = .007); vWF:CBA
and age (r = −0.636, P = .003); AA AUC and PCV (r = 0.535, P = .02);
PCV and age (r = −0.506, P = .02); urea and age (r = −0.628, P = .001);
urea and vWF:CBA (r = −0.617, P = .004); urea and wVF:Ag:vWF:CBA
(r = 0.642, P = .002); and with urea and PCV (r = −0.522, P = .02).
There was no significant correlation between other variables (Table 2).
4 | DISCUSSION
This study assessing primary hemostatic function in dogs with AKI
found that COL-, but not AA- or ADP-, induced platelet aggregation
as measured by MEPA was significantly decreased in dogs with AKI
compared to a control population of healthy dogs; however, aggrega-
tion remained within reference intervals. Although there was no dif-
ference in vWF:Ag concentration, vWF:Ag:vWF:CBA was significantly
higher in dogs with AKI, indicating that less vWF was bound to COL
possibly due to a reduction in higher molecular weight (MW) vWF
multimers in dogs with AKI. This was supported by the correlation
between vWF:Ag:vWF:CBA and both creatinine and urea. Although
BMBT was marginally prolonged in dogs with AKI, there was no corre-
lation between BMBT and any other variables. However, these afore-
mentioned results must be interpreted in light of the difference in the
lower PCV and higher platelet count in the dogs with AKI.
Our study suggests that COL-inducted platelet aggregation is
impaired in dogs with AKI. Collagen found in vessel walls and base-
ment membranes are important in normal platelet function as it
directly binds to glycoprotein (GP) VI receptors and integrin α2β1, and
indirectly via vWF binding to GPIb-IX-V complex which are integral
processes for normal platelet function.20 Dogs with CKD also have
impairment in COL-induced platelet function as measured by platelet
function analyzer's COL- and ADP-induced platelet closure time.13
However AA-, ADP-, or COL-induced platelet aggregation as mea-
sured by LTA are normal in dogs with CKD12 and experimentally
induced kidney injury.10 One case report describes a dog with CKD
with decreased AA- and ADP-induced LTA; however, COL-induced
aggregometry was not performed.21 The difference in results might
be explained by the different nature of kidney injury and the differ-
ence in methodology of testing platelet function.
There are differences between MEPA and LTA. Light transmit-
tance aggregometry has been traditionally considered the gold stan-
dard of platelet function tests,22 and like MEPA, platelet aggregation
is measured after activating platelets with agonists including AA, ADP,
and COL. The advantages of MEPA, however, are that it is a point-of-
care test which utilizes whole blood, as opposed to platelet-rich
TABLE 1 Measured variables in the
acute kidney injury (AKI) and control
groups
Variables
Reference
intervals AKI group
Control
group P value
Age (y) 9.7 (±2.9) 4.3 (±1.9) .01*
Body weight (kg) 15.1 [6.1, 37.4] 36.20 [29.0, 48.6] .01*
PCV (%) 37-55 34.7 (±8.8) 46.1 (±3.6) .001*
Plt (×103/μL) 177-398 350 [301, 516] 241.00 [227, 251] .01*
Creatinine (g/dL) 0.7-1.8 8.5 (±4.3) 1.2 (±0.2) <.001*
Urea (mg/dL) 5-30 135.1 (±62.4) 6.5 (±1.01) <.001*
AA AUC 13.6-74.9 28.4 (±22.0) 42.3 (±7.5) .14
ADP AUC 10.1-103.7 46.0 [21.5, 64.3] 60.50 [46.5, 62.0] .70
COL AUC 6.2-105.3 36.9 (±17.7) 54.9 (±11.2) .05*
vWF:Ag (%) 70-180 125.6 (±28.1) 104.7 (±39.4) .08
vWF:CBA 50-170 55.0 (±16.1) 88.7 (±26.9) .04*
vWF:Ag:vWF:CBA 0.5-1.7 2.2 [1.9, 2.6] 1.1 [1.1, 1.2] .001*
All variables are reported as mean (±SD), other than body weight, platelet count, and ADP AUC, which
are reported as median [25th, 75th percentile].
Abbreviations: AA, arachidonic acid; ADP, adenosine diphosphate; AUC, area under the curve; COL,
collagen; Plt, platelet count; vWF:Ag, von Willebrand factor antigen; vWF:CBA, von Willebrand factor
collagen binding activity; vWF:Ag:vWF:CBA, von Willebrand factor antigen to von Willebrand factor
collagen binding activity ratio.
*P < .05 was considered significant.
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plasma (PRP) which is required for LTA, minimizing preanalytical and
analytical variables. The use of whole blood reduces the time to analy-
sis, obliterates the need to produce PRP in which platelets could be
activated in the process, and the sample used is more physiological
having erythrocytes present which augments platelet function by
increasing AA release and expression of αIIbβ3 receptors.20 Multiple
electrode impedance platelet aggregometry has also been vali-
dated23,24 and used in dogs to assess platelet function in the setting
of sepsis14 and hemorrhagic shock.25
When assessing platelet function, erythrocyte concentration must
be taken into consideration, as it affects platelet function by 1 or more
mechanisms. Erythrocytes release ADP and thromboxane which aug-
ment platelet activation and aggregation and scavenge nitric oxide
which is a platelet antagonist.26 Anemia results in decrease in AA- and
ADP-induced, but not COL-induced, platelet aggregation in dogs25 and
in people.27,28 Therefore, it is unlikely that the lower PCV in the AKI
group would have influenced the decrease in COL- induced platelet
aggregation in this study. There is positive linear correlation between
platelet count and platelet aggregation measured by MEPA.29-32 There-
fore, it is possible that a type-II error might have occurred with AA- and
ADP-induced platelet aggregation due to the significantly higher plate-
let count in the AKI group in the current study.
Although it is known that primary hemostatic dysfunction occurs
in dogs with CKD, it is important to differentiate AKI from CKD as
there are differences in platelet aggregation in people with AKI versus
CKD.8 It is also important to consider the method of platelet function
analysis, as there are differences in platelet aggregation measured by
LTA and MEPA,8 which is hypothesized to be due to the lack of eryth-
rocytes in the PRP used in LTA. It is difficult to compare our results
with other studies in dogs, due to the difference in etiology of kidney
injury, as well as the difference in platelet function testing.
We measured vWF:Ag and vWF:CBA to determine if vWF played
a role in bleeding tendencies in dogs with AKI. As vWF:Ag in the AKI
group was no different to the control group and was slightly higher
than reported values,16,17 our study confirms that it is not a decrease
or deficiency in vWF concentrations which contributes to bleeding
tendencies in dogs with AKI. Our study results more closely reflect an
acquired type II vWD phenotype, as the AKI group had significantly
higher vWF:Ag:vWF:CBA compared to the control group. Acquired
von Willebrand syndrome (AVWS) occurs in people with uremia and is
defined as an acquired bleeding disorder with clinical and laboratory
features similar to inherited von Willebrand disease.33 Although
AVWS occurs in many disease processes in people, the incidence of
AVWS in uremic patients is rare, with only 15 cases reported so far,
which accounts for only 4% of underlying causes of AVWS in total.33
The proposed mechanism of AVWS in people is due to increased pro-
teolytic degradation of vWF by specific proteases.33,34 This proposed
mechanism has been supported by findings of low vWF ristocetin
(vWF:RCo) to vWF:Ag ratio, which is another method for detecting
decreased large MW vWF in people, as well as a lack of large MW
vWF on multimeric analysis in CKD.35 However, factors other than
vWF:Ag concentration or vWF multimeric pattern might play a role in
bleeding tendencies in uremic people with CKD, as normal, increased,
or decreased vWF:Ag, vWF:RCo, and multimeric pattern occurs with
and without prolonged bleeding times.35-37 These variable results sug-
gest that the underlying cause of bleeding tendencies is not
completely understood, possibly being multifactorial or affected by
other comorbidities or confounding factors.
Primary hemostatic disorder occurs in dogs with experimentally
induced CKD, indicated by a prolongation in BMBT.11 However, the
underlying mechanism is unknown as there are increased vWF:Ag
concentrations, no change in multimeric distribution of vWF,11 and
normal AA-, ADP-, and COL-induced LTA.10 This is contrary to our
findings which characterized primary hemostatic disorders in naturally
occurring AKI with decreased COL-induced platelet aggregometry,
and abnormal binding of vWF to COL, as indicated by the high vWF:
Ag:vWF:CBA ratio. The difference in our findings is likely associated
with the different nature of disease, as well as the different methods
in primary hemostatic assays, though we cannot exclude other causes
of primary hemostatic dysfunction not measured in our study.
Buccal mucosal bleeding time was used to evaluate primary hemo-
static function as it is readily available to most veterinary practitioners.
Our study found prolonged BMBT in dogs with naturally occurring AKI,
compared to known reference intervals of 1.7 to 4.8 minutes.18,19 As
we did not compare BMBT to the control group under the guidance of
our ethics committee, we performed Spearman's rank test to measure
correlation between BMBT and other measured variables. There was
no correlation between BMBT and other primary hemostatic function
tests, contrary to a negative correlation between vWF:Ag and BMBT in
dogs with type I-III vWD and dogs with thrombocytopathia.38 Uremic
dogs can have normal39 or prolonged BMBTs, with mean (SD) of 12.60
(±6.05) minutes,19 and 7.0 (±0.4) minutes.11 These differences in BMBT
might be due to the etiology of uremia or known variability in the
BMBT measurement technique.19,40 Interobserver variability was mini-
mized in our study by having only 2 of the authors performing the test,
although intraobserver variability would have been present.40 Buccal
mucosal bleeding time might have been longer if the platelet count in
our study population was no different to the control group, and the test
procedure was not discontinued in the dog which had BMBT of
10 minutes or greater. We conclude that either BMBT is not appropri-
ate for measuring primary hemostatic function in dogs with AKI due to
these variabilities or perhaps there are other mechanisms of primary
hemostatic dysfunction not measured in our study which caused the
prolonged BMBT.10,11
There are several limitations to our study. The AKI group had
lower AA- and ADP-induced platelet aggregation compared to the
control group which was not statistically significant. As this is a pilot
study, the small sample size might have contributed to a type II error.
A sample size of 26 dogs in each group would be required to detect a
difference in platelet aggregation between the 2 groups, should such
a difference exist. The small sample size might have also contributed
to a type II error in vWF:Ag concentrations, in which 115 dogs would
be required to detect a difference between the 2 groups, should such
a difference exist. There were many variables with strong correlation
which did not reach significance, in which 24 dogs would be required
in each group to reach significant difference if present. In addition, as
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already discussed, the difference in PCV and platelet count might
have also influenced our results. If PCV and platelet count were stan-
dardized between the 2 groups, there might be decreased or
increased difference in platelet aggregation respectively.
We aimed to characterize platelet function in dogs with AKI; how-
ever, we also included dogs with AoCKD. This inclusion of dogs with
CKD might limit our ability to purely state that the findings are spe-
cific to AKI, as primary hemostatic function might have been contrib-
uted from mechanisms associated with CKD also. Although our study
design excluded known causes of AKI, other unknown comorbidities
might have influenced the results.
In conclusion, we found that dogs with AKI have abnormal primary
hemostatic function, with decreased COL-induced MEPA and abnor-
mal vWF:CBA. Buccal mucosal bleeding time is not an appropriate
test to determine if primary hemostatic dysfunctions are present in
dogs with AKI. This study did not determine if primary hemostatic
dysfunctions found in this study are associated with clinical bleeding.
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